S28 peptidases: lessons from a seemingly 'dysfunctional' family of two

BMC Biology

Volumn 8, Issue , 2010, Pages

  Kozarich, John W ^a  

^a ACTIVX BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE II; LYSOSOMAL PRO X CARBOXYPEPTIDASE; LYSOSOMAL PRO-X CARBOXYPEPTIDASE;

ARTICLE; CHEMICAL STRUCTURE; COMPARATIVE STUDY; ENZYME SPECIFICITY; GENETICS; HUMAN; METABOLISM; MULTIGENE FAMILY; PROTEIN CONFORMATION;

CARBOXYPEPTIDASES; DIPEPTIDYL-PEPTIDASES AND TRIPEPTIDYL-PEPTIDASES; HUMANS; MODELS, MOLECULAR; MULTIGENE FAMILY; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY;

EID: 77954309438     PISSN: None     EISSN: 17417007     Source Type: Journal    
DOI: 10.1186/1741-7007-8-87     Document Type: Note

References (10)

1. Soisson SM, Patel SB, Abeywickrema PD, Byrne NJ, Diehl RE, Hall DL, Ford RE, Reid JC, Rickert KW, Shipman JM, Sharma S, Lumb KJ. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase. BMC Struct Biol 2010, 10:16.
2. Mallela J, Yang J, Shariat-Madar Z. Prolylcarboxypeptidase: a cardioprotective enzyme. Int J Biochem Cell Biol 2009, 41:477-481.
3. Rosenblum JS, Kozarich JW. Prolyl peptidases: a serine protease subfamily with high potential for drug discovery. Curr Opin Chem Biol 2003, 7:496-504.
4. Ollis DL, Cheah E, Cygler M, Dijkstra B, Frolow F, Franken SM, Harel M, Remington SJ, Silman I, Schrag J, Sussman JL, Verschueren KHG, Goldman A. The alpha/beta hydrolase fold. Protein Eng 1992, 5:197-211.
5. Egloff MP, Marguet F, Buono G, Verger R, Cambillau C, van Tilbeurgh H. The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate. Biochemistry 1995, 34:2751-2762.
6. Aertgeerts K, Ye S, Tennant MG, Kraus ML, Rogers J, Sang BC, Skene RJ, Webb DR, Prasad GS. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation. Protein Sci 2004, 13:412-421. 2286704, 14718659.
7. Chiravuri M, Huber BT. Aminodipeptidase inhibitor-induced cell death in quiescent lymphocytes: a review. Apoptosis 2000, 5:319-322.
8. Danilova OV, Tai AK, Mele DA, Beinborn M, Leiter AB, Greenberg AS, Perfield JW, Defuria J, Singru PS, Lechan RM, Huber BT. Neurogenin 3-specific dipeptidyl peptidase-2 deficiency causes impaired glucose tolerance, insulin resistance, and visceral obesity. Endocrinology 2009, 150:5240-5248.
9. Danilova O, Li B, Szardenings AK, Huber BT, Rosenblum JS. Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor. Bioorg Med Chem Lett 2007, 17:507-510. 1828633, 17055271.
10. Maes MB, Lambeir AM, Van der Veken P, De Winter B, Augustyns K, Scharpe S, De Meester I. In vivo effects of a potent, selective DPPII inhibitor: UAMC00039 is a possible tool for the elucidation of the physiological function of DPPII. Adv Exp Med Biol 2006, 575:73-85.